Skip to content

Nurix Therapeutics, Inc. NRIX Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Nuvation Bio logo
Nuvation BioNUVB
$1.41M+68.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$486K-52.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$2.88M+24.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s lease liability payments - due year two?
Nurix Therapeutics, Inc. (NRIX) reported lease liability payments - due year two of $9.18M in Q3 2025.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.